Trial Profile
Retrospective study of pembrolizumab (Keytruda) or nivolumab (Opdivo) with or without concurrent bevacizumab for recurrent high-grade glioma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2018 New trial record
- 31 Aug 2018 Results published in the Neurology